

Q1
Conclude
effective amount of a compound that promotes the production of extracellular matrix from an extracellular matrix-producing cell.

Q2
3. The pharmaceutical composition according to claim 1, which exhibits an inhibitory effect on glomerular nephritis, diabetic nephropathy or tissue fibrosis caused by the overproduction and the accumulation of extracellular matrix.

Q3
11. The pharmaceutical composition according to any of claims 1 to 4, which is a therapeutic or preventive agent.

12. The pharmaceutical composition according to claim 3, wherein the glomerular nephritis, diabetic nephropathy or tissue fibrosis is glomerular nephritis, diabetic nephropathy or tissue fibrosis, respectively, caused by the abnormal proliferation of mesangium cells.

Q4
25. A method for inhibition of glomerular nephritis, diabetic nephropathy or tissue fibrosis caused by the overproduction and the accumulation of extracellular matrix, said method comprising administering an effective amount of a compound having an inhibitory effect on the biological activity of galectin-3, to a subject which needs said inhibition, to thereby inhibit the overproduction and accumulation of extracellular matrix.

Q5
27. The method according to claim 25, for inhibition of glomerular nephritis, diabetic nephropathy or tissue fibrosis caused by the overproduction and the accumulation of extracellular matrix.

28. The method according to claim 27, wherein the biological activity of galectin-3 is to promote the production of extracellular matrix from an extracellular matrix-producing cell.

Q6
35. The method according to any of claims 25 to 28, which is for therapeutic or preventive treatment.

Amendment Under 37 C.F.R. § 1.111
U.S. Serial No. 09/744,328

Alf
Andrade 36. The method according to claim 27 or 28, wherein the glomerular nephritis,
diabetic nephropathy or tissue fibrosis is glomerular nephritis, diabetic nephropathy or tissue
fibrosis, respectively, caused by the abnormal proliferation of mesangium cells.
